Seventh Sense Biosystems Inc. (7SBio) announced that a new blood collection device called TAP has received U.S. Food and Drug Administration 510(k) clearance. The technology represents a landmark innovation in the blood collection industry where one billion blood draws are performed each year for diagnostic testing.
HealthSTAR Communications announced the launch of HealthSTAR Fusion Group, an important new addition to its strategic network of companies.
ProMIS Neurosciences announced it has issued a scientific white paper entitled “Results from recent Alzheimer’s disease trials validate the ProMIS approach.”
The U.S. Supreme Court cleared a subsidiary of biotech company Thermo Fisher Scientific Inc. of infringing a genetic-testing kit patent held by Promega Corp.
Philips announced the introduction of a new platform for image guided therapy that enables doctors to combine the use of several medical scanners, imaging data and large screen displays as they perform minimally invasive surgeries.
CVS Health Corp. said its pharmacy chain had removed artificial trans fats, which have been linked to rising rates of heart diseases, from its store-branded food products well ahead of a June 2018 federal deadline.
Ocular Therapeutix’s NDA resubmission for DEXTENZA 0.4 mg for ocular pain occurring after ophthalmic surgery was accepted as a filing for review by FDA.
Lexington, Mass.-based Agenus quietly filed with the U.S. Securities and Exchange Commission (SEC) that it was halting the company’s clinical trial of its cancer vaccine Prophage.
Chief executive officers from more 16 large manufacturing companies – including pharma leaders from Celgene, Dow Chemical, Eli Lilly, Merck and Pfizer – penned a letter to Congressional leaders in support of a Republican-backed tax reform plan.
Hours after Bristol-Myers Squibb announced a $2 billion stock buyback plan, billionaire investor Carl Icahn snapped up a “large stake” of BMS stock, which sent shares soaring.
Join Lewis Barr, General Counsel and VP of Privacy at Janrain and Eleanor Treharne-Jones, VP Consulting at TRUSTe for the first installment of our General Data Protection Regulation (GDPR) webinar series.
Kaiser Permanente Study Finds Testosterone Replacement Therapy Reduces Cardiovascular Risk Among Men with Androgen Deficiency
Men who used testosterone replacement therapy to treat symptoms of androgen deficiency had a 33 percent lower risk of cardiovascular events such as heart attacks and stroke compared to those who did not receive any hormone therapy. The findings from the Kaiser Permanente study were published in JAMA Internal Medicine.
The U.S. Supreme Court turned away an appeal of a Maryland state court jury verdict ordering Boston Scientific Corp. to pay $308 million to a patent licensor.
For the world’s drug makers 2016 was a year of two halves. Dealmaking and venture funding held up over the first two quarters, buoyed by the retreating bull market. However, as the US presidential election loomed ever closer, companies went into lockdown. Meanwhile, the medtech sector demonstrated that greater efforts are needed to foster innovation if it is to thrive. These findings and more were released as part of the Pharma & Biotech 2016 in Review and Medtech 2016 in Review reports by EP Vantage, the editorial arm of life science market intelligence firm Evaluate.
Only some doses of Trevena’s experimental opioid painkiller were found as effective as morphine in two late-stage studies, though the drug met its main study goals.
Amphastar Pharmaceuticals Inc. said the U.S. Food and Drug Administration had rejected its application to market an intranasal version of the emergency opioid-overdose treatment, naloxone.
Corbus Pharmaceuticals had a terrific 2016, with stock climbing 412 percent. Jim Crumly, writing for The Motley Fool, takes a look at the company and whether it can continue that trend for 2017.
Cambridge, Mass.-based Sarepta Therapeutics won a Rare Pediatric Disease Priority Review Voucher from the U.S. Food and Drug Administration when Exondys 51 was approved for Duchenne muscular dystrophy. The company announced that it had auctioned off its voucher for $125 million.
This webinar will focus on the importance of value proposition design (through the lens of the customer) and its applications to healthcare organizations. It will address how this is the foundational step for creating transformative healthcare business models. Participants will gain exposure to several design thinking tools that can be applied immediately.
The agenda will feature speakers who will share what achieving gender parity means to them, as well as highlight the groundbreaking work being done at large organizations.